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Abstract 
The 5-hydroxytryptamine type-3 receptor antagonist, tropisetron, is in clinical use as an anti-
emetic drug.  This compound also exerts both potentiating and inhibitory effects on the glycine 
receptor chloride channel.  The inhibitory effects occur at micromolar concentrations whereas the 
potentiating effects are shown here to occur at femtomolar concentrations at the homomeric α1 
receptor.  Potentiation occurred only when tropisetron was applied in the presence of glycine.  This 
investigation also sought to identify molecular determinants of tropisetron inhibition at the α1 glycine 
receptor by serially mutating residues located in or near known ligand-binding sites.  We discovered 
that conservative mutations to N102 ablated tropisetron inhibition without affecting the magnitude or 
sensitivity of tropisetron potentiation.  Several lines of evidence, including a structure-activity analysis 
of tropisetron, atropine and SB203186, suggest that N102 may bind to the tropisetron tropane nitrogen 
via H-bonding.  Mutation of the N125 residue in the β subunit, which corresponds to N102 in the α1 
subunit, had little effect on tropisetron inhibitory potency.  These results show that N102 is required 
for tropisetron inhibition but not potentiation and that inhibitory tropisetron binds in different 
orientations at different subunit interfaces.  To our knowledge, tropisetron is the most exquisitely 
sensitive compound yet identified for a cys-loop ion channel receptor.   
 
 
Keywords: ligand-gated ion channel; cys-loop receptor; 5-HT3 receptor antagonist; tropeine; 
femtomolar; binding site; molecular structure and function. 
 
Running title: Tropisetron modulation of the glycine receptor 
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Introduction 
Glycine receptor (GlyR) Cl- channels mediate inhibitory neurotransmission at defined synapses 
in the spinal cord, brainstem, cerebellum and retina (Legendre 2001; Lynch 2004).  In addition, 
extrasynaptic GlyRs are widely distributed throughout the central nervous system (e.g., Flint et al. 
1998; McCool and Farroni 2001).  GlyRs are members of the cys-loop family of ligand-gated ion 
channel receptors which also includes cation-permeable nicotinic acetylcholine receptors (nAChRs), 
5-hydroxytryptamine type-3 receptors (5-HT3Rs) and anion-permeable GABA type-A receptors 
(GABAARs).  Functional cys-loop receptors comprise an assembly of 5 homologous membrane-
spanning subunits arranged symmetrically around a central water-filled pore (Unwin 2005).   The 
GlyR can be formed either as a homomer of α subunits or as a heteromer of α and β subunits in an 
invariant 2α:3β stoichiometry (Griffon et al. 1999; Grudzinska et al. 2005). All cys-loop receptor 
subunits consist of a large extracellular ligand-binding domain followed by a transmembrane domain 
that comprises a bundle of 4 α-helices.  Ligand-binding pockets are located at the subunit interfaces 
approximately midway between the top and bottom of the ligand-binding domains (Brejc et al. 2001).  
This pocket is lined by 3 loops (labelled A, B and C) from one subunit that form the ‘principal’ (or +) 
side of the ligand-binding pocket, whereas 3 β-strands (labelled D, E and F) from the adjacent subunit 
form the ‘complementary’ (or -) side.   
GlyRs have recently emerged as potential therapeutic targets for anti-spasticity and anti-
inflammatory analgesic drugs (Laube et al. 2002; Zeilhofer 2005; Lynch and Callister 2006).   Their 
involvement in the regulation of motor control via local spinal reflex circuits is dramatically illustrated 
by the motor deficits that result when glycinergic current is reduced in the human hereditary disorder, 
hyperekplexia (Bakker et al. 2006).  This disorder is characterized by an exaggerated reflex response 
to unexpected stimuli, which typically takes the form of a complete but temporary muscular rigidity, 
leading to a loss of balance and an unprotected fall.  A role for GlyRs in inflammatory pain 
sensitization is implied by the observation that prostaglandin E2 mediates inhibition of α3 subunit-
containing GlyRs in dorsal horn nociceptive neurons (Ahmadi et al. 2002; Harvey et al. 2004).  This 
process is likely to result in the disinihibition of firing activity in nociceptive projection neurons, 
thereby increasing the transmission of nociceptive stimuli to the brain (Zeilhofer 2005; Lynch and 
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Callister 2006).  Together, these observations imply that compounds that potentiate (i.e., restore) GlyR 
current flux may be useful as leads for novel analgesic or muscle relaxant drugs.   
Orally-administered tropisetron is used clinically for treating postoperative and chemotherapy-
induced emesis (Haus et al. 2004). Its therapeutic effects are mediated via antagonism of the 5-HT3R, 
which is strongly expressed in medullary emesis control centres (Farber et al. 2004).  However, 
tropisetron also has potent effects on the GlyR.  It has been shown to potentiate glycine currents at 
nanomolar concentrations, but produce inhibition at higher (micromolar) concentrations (Chesnoy-
Marchais 1996; Supplisson and Chesnoy-Marchais 2000).  The high potency, strong potentiating 
effects and excellent oral bioavailability of tropisetron render it suitable as a therapeutic lead 
compound for the development of novel GlyR-specific drugs.  However, a significant problem with 
existing tropeine derivatives is that they are not specific for the GlyR (Maksay et al. 2004).  Although 
structure-activity analyses of tropisetron analogues have provided insight into the tropisetron structural 
moieties required for potentiation and inhibition (Chesnoy-Marchais 1996; Maksay 1998; Chesnoy-
Marchais 1999; Chesnoy-Marchais et al. 2000; Maksay et al. 2004), there are as yet few clues as to the 
location or structure of the GlyR tropisetron binding sites. 
As the 5-HT3R and GlyR are both members of the cys-loop receptor family, it is reasonable to 
hypothesise that they may share common or overlapping tropisetron binding sites.  Although little is 
known about tropisetron binding at the 5-HT3R, recent studies have produced a consensus model for 
the binding of the structurally-related compound, granisetron, in the agonist-binding pocket (Maksay 
et al. 2003; Thompson et al. 2005; Yan and White 2005).  It should be noted, however, that 
granisetron binds to the α1 5-HT3R with nanomolar affinity (Schreiter et al. 2003; Thompson et al. 
2005; Yan and White 2005), whereas it inhibits the α1 GlyR with an IC50 of around 100 µM 
(Chesnoy-Marchais et al. 2000).  Furthermore, it is not known whether the inhibitory or potentiating 
tropisetron-binding sites of the GlyR overlap with each other or whether either of them lie in the 
agonist-binding pocket.  Thus, the extent to which the 5-HT3R granisetron binding site provides a 
useful template for modelling the structure of either the potentiating or inhibitory GlyR tropisetron 
binding sites remains to be seen. 
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To understand the molecular interactions crucial for high potency tropisetron potentiation, it is 
first necessary to characterise the molecular determinants of both its inhibitory and potentiating 
effects.  The present study identifies a specific molecular determinant of tropisetron inhibition.  During 
the course of these experiments, we also found that tropisetron potentiates the GlyR at surprisingly 
low concentrations. 
 
Materials and Methods 
 GlyR  mutagenesis and expression 
The human GlyR α1 subunit cDNA was subcloned into the pCIS2 plasmid vector.  The human 
β subunit was subcloned into the pIRES2-EGFP plasmid vector (Clontech, Palo Alto, CA, USA). Site-
directed mutagenesis was performed using the QuickChange mutagenesis kit (Stratagene, La Jolla, 
CA, USA) and the successful incorporation of mutations was confirmed by sequencing the clones. 
HEK293 cells were transfected using a calcium phosphate precipitation protocol. When co-
transfecting the GlyR α and β subunits, their respective cDNAs were combined in a ratio of 1:20. 
After exposure to transfection solution for 24 hrs, cells were washed twice using phosphate buffered 
saline and used for recording over the following 24 - 72 hrs. 
 
Electrophysiology 
Cells were observed using a fluorescent microscope and currents were measured by whole cell 
recording. Cells were perfused by a control solution that contained (in mM): 140 NaCl, 5 KCl, 2 
CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, with the pH adjusted to 7.4 with NaOH. Patch pipettes were 
fabricated from borosilicate hematocrit tubing (Vitrex, Modulohm, Denmark). Pipettes had tip 
resistances of 1.5 - 3 MΩ when filled with pipette solution containing (in mM): 145 CsCl, 2 CaCl2, 2 
MgCl2, 10 HEPES, 10 EGTA, with the pH adjusted to 7.4 with NaOH. Cells were voltage-clamped at 
–40 mV at room temperature (19 – 22 oC) and membrane currents were recorded using an Axopatch 
1D amplifier and pCLAMP9.2 software (Axon Instruments, Union City, CA, USA).  GFP 
fluorescence was used to identify cells expressing the GlyR β subunit.  The successful incorporation of 
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β subunits into functional receptors was also determined by their reduced picrotoxin sensitivity 
(Pribilla et al. 1992), as discussed below.   
   Picrotoxin (Sigma, St Louis, MO) was stored frozen as a 100 mM stock in dimethylsulfoxide.  
Tropisetron (Sigma), atropine (Sigma) and SB 203186 (Alexis Biochemicals) were made as 100 mM 
stocks in water and stored at 4 oC for up to 2 weeks. 
Solution exchanges were performed using a parallel array of microtubular barrels through which 
solutions were gravity-fed into the recording chamber.  As the solution flow rate was typically 1 
ml.min-1 and the microtubules had an internal diameter of 300 µm, the flow velocity was around 0.2 
m.s-1.  Barrel mouths were positioned to within 500 µm of target cells and rapid complete solution 
exchange was effected by moving the barrels laterally under the control of a manual 
micromanipulator.  Solution exchange time constants of 100 ms were routinely achieved between 
adjacently placed barrels.   Cells, cultured on glass coverslips, were placed in the recording chamber.  
Given the extreme sensitivity of the GlyRs to tropisetron, we assumed that all unpatched cells on a 
coverslip were contaminated after a single tropisetron application to a single cell.     For this reason, 
we recorded from only one cell per coverslip and the recording chamber was thoroughly rinsed with 
control solution before a new coverslip was introduced.     
 
Data analysis 
Results are expressed as mean ± standard error of the mean of 3 or more independent 
experiments. The Hill equation was used to calculate the saturating current magnitude (Imax), half-
maximal concentration (EC50) and Hill coefficient (nH) values for glycine activation.  A similar 
equation was also used to calculate the half maximal concentrations for tropisetron potentiation (EC50) 
and inhibition (IC50). Inhibitory dose-responses were quantitated relative to the maximum potentiation.  
All curves were fitted using a non-linear least squares algorithm (Sigmaplot 9.0, Jandel Scientific, San 
Rafael, CA, USA). Statistical significance was determined by paired or unpaired Student’s t-test, as 
appropriate, with P < 0.05 representing significance. 
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Results 
Tropisetron modulation of homomeric α1 GlyRs 
Sample glycine dose-response relationships for α1 and α1β GlyRs are shown in Fig. 1A.  The 
averaged dose-response curves are presented in Fig. 1B, with mean parameters of best fit displayed in 
Table 1.  The incorporation of β subunits into heteromeric α1β GlyRs results in a characteristic 
reduction in receptor sensitivity to picrotoxin (Pribilla et al. 1992).  To confirm the successful 
incorporation of β subunits, the effects of 10 µM picrotoxin were measured in the presence of an EC30 
glycine concentration at both the α1 and α1β GlyRs.  Examples of the effects of 10 µM picrotoxin on 
putative homomeric and heteromeric receptors are shown in Fig. 1C.  The percentage of original current 
remaining in 10 µM picrotoxin, averaged from 4 cells expressing each receptor, is presented in Table 1.  
The results show that co-expression of α1 and β subunits indeed results in the formation of heteromeric 
receptors.  Fig. 1 also describes the glycine and picrotoxin sensitivities of 3 mutant receptors which will 
be considered below.    
We were surprised to find that femtomolar concentrations of tropisetron caused significant 
potentiation of submaximal glycine responses in the α1 GlyR.  The biophysical implications of such 
high sensitivity are considered in the Discussion.   Briefly, the unbinding rate should be so slow that 
binding is essentially irreversible and thus, the time course of tropisetron potentiation should provide a 
reasonable estimate of the tropisetron binding rate (kon).  To investigate this rate, we quantitated the 
time course of the potentiation induced by 1 pM tropisetron.  A sample experiment is shown in Fig. 
2A, with the tropisetron-mediated current change plotted against the tropisetron exposure time in Fig. 
2B.  This plot was fitted with a time constant of 39 s.  The time constant averaged from 4 similar 
experiments was 107 ± 26 s.  As considered in detail below, this value corresponds well with the 
theoretical maximum diffusion limited rate of 109 M-1 s-1.  As shown in Fig. 2A (lower panel), a 100 s 
application of 1 pM tropisetron in the absence of glycine did not significantly potentiate   a subsequent 
response to glycine.  Similar results were seen in each of 8 cells. 
In continuous electrophysiological recordings, we found that tropisetron potentiation showed 
no significant reversal for periods of up to 30 min after washout.  To test its reversibility over a longer 
(5 hr) period, we incubated cells in petri dishes for 5 min in control bath solution containing 10 fM 
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tropisetron plus 20 µM (EC30) glycine.  We then removed the tropisetron from the cells by thorough 
washing, and incubated the cells in standard culture medium for 5 hrs.  We then tested whether GlyRs 
could be potentiated by 1 pM tropisetron.  In a total of 4 cells investigated in this manner, we found 
that 20 µM glycine produced almost saturating (EC90) glycine current suggestive of strong tropisetron 
potentiation.  Furthermore, 1 pM tropisetron had no significant effect on any of the 4 cells.  This 
indicates that tropisetron potentiation is completely irreversible over a 5 hr period. 
Tropisetron potentiating and inhibitory dose-response relationships were measured in the 
presence of a 20 µM (EC30) glycine concentration.  Because the effects of tropisetron were 
irreversible, we measured dose-response relationships by applying progressively higher tropisetron 
concentrations at approximately 3 minute intervals.  We recognise that this was unlikely to be 
sufficient time for tropisetron to equilibrate with its site, and thus our results may be subject to a 
systematic error.  Nevertheless, we considered that this approach should provide an order of 
magnitude approximation and should also be useful for assessing the effects of mutagenesis on the 
sensitivity of tropisetron potentiation.  Samples of the potentiating response of the α1 GlyR to 
increasing concentrations of tropisetron in the femtomolar range are shown in Fig. 2B (upper panel) 
and results averaged from 5 cells are presented in Fig. 2C (lower panel).   The data were fitted with 
mean EC50 and nH values of 4.4 ± 2.5 fM and 0.7 ± 0.2, respectively (both n = 5).  Tropisetron 
induced a maximum potentiation of 83 ± 10 % (n = 5) of the EC30 glycine current. The tropisetron 
inhibitory potency was measured in a similar manner.  Examples of EC30 glycine currents recorded in 
the presence of inhibitory (micromolar) concentrations of tropisetron are shown in Fig. 2C (upper 
panel), with results averaged from 7 cells presented in Fig. 2C (lower panel).  The parameters of best 
fit for tropisetron inhibition are shown in Table 1. 
The glycine-dependence of tropisetron potentiation and inhibition was determined.  Fig. 3A 
(left panel) shows examples of the effects of a maximally potentiating (10 nM) concentration of 
tropisetron on currents activated by EC30, EC70 and EC90 glycine in different cells expressing α1 
GlyRs.  Results averaged from 5 cells at each glycine concentration reveal that the percentage current 
increase declines as glycine concentration increases (Fig. 3A, right panel).  A previous study noted a 
generally similar phenomenon, with the exception that no potentiation was observed at glycine 
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concentrations greater than EC30 (Supplisson and Chesnoy-Marchais 2000).  Fig. 3B (left panel) 
shows examples of the inhibitory effect of 200 µM tropisetron on currents activated by EC30, EC70 
and EC100 glycine in a cell expressing homomeric α1 GlyRs.  Results of similar experiments averaged 
from 4 cells confirm that tropisetron inhibition is progressively overcome by increasing the glycine 
concentration (Fig. 3B, right panel).  As discussed in detail below, this result is consistent with 
tropisetron acting as a competitive antagonist. 
   
A molecular determinant of tropisetron inhibition 
We hypothesised that the inhibitory tropisetron-binding site coincides with one of the known ligand-
binding sites of the GlyR. Accordingly, we screened tropisetron against α1 GlyRs containing mutations to a 
variety of known or suspected ligand-binding sites.  We investigated the principal ligand-binding domain A 
(via mutations A101C and N102A), principal ligand-binding domain B (via F159A and Y161C), principal 
ligand-binding domain C (via K200A, H201A, Y202F, N203A, T204A and Y207A) and complementary 
ligand-binding domain D (via F63Yand R65A).  All of these residues have previously been identified as 
either glycine binding residues or as residues that lie adjacent to glycine binding residues (Vandenberg et al. 
1992b; Vandenberg et al. 1992a; Schmieden et al. 1993; Rajendra et al. 1995; Vafa et al. 1999; Han et al. 
2001; Grudzinska et al. 2005).   By inspection of a molecular model of the GlyR extracellular domain (Nevin 
et al. 2003), we identified and tested several other potential ligand-binding residues in and around the ligand-
binding pocket via the N46Q, S129V, A137S, I153T and D180E mutations.   We also tested the alcohol-
binding site (via S267C) (Mihic et al. 1997) and the inhibitory zinc-binding site (via H107N and H109N) 
(Harvey et al. 1999; Nevin et al. 2003).  Residues homologous to F63, R65, H101, D180, K200 and Y207 in 
the GlyR α1 subunit have been proposed to contribute to the granisetron-binding site in the 5-HT3R (Maksay 
et al. 2003; Thompson et al. 2005; Yan and White 2005).  Many of the residues investigated here are 
displayed in the model in Fig. 4. 
With the exception of Y207A, we obtained robust glycine-gated currents upon recombinant expression 
of homomeric α1 GlyRs incorporating any of the above mutations.   Glycine concentrations of up to 50 mM 
failed to significantly activate the α1Y207A GlyR, which may not be surprising given its role as a glycine 
binding site (Grudzinska et al. 2005).  All mutant GlyRs were screened at a strongly inhibiting (500 µM) 
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tropisetron concentration in the presence of an EC30 glycine concentration.  Results averaged from at least 4 
cells expressing each mutant GlyR, together with the EC30 glycine concentration required to activate each 
receptor, are listed in Table 2.  Of all the mutants tested, only the N102A mutation resulted in the complete 
elimination of tropisetron inhibition, to the effect that 500 µM tropisetron induced a strong potentiation.  
   This finding prompted us to test the effects of the more conservative substitutions, N102D and 
N102Q, on tropisetron inhibitory potency.  As summarised in Table 2, all three N102 mutations acted 
similarly to abolish inhibition without significantly affecting the maximum tropisetron potentiating 
amplitude.   Because N102Q is the most conservative of these substitutions, we analysed the α1N102Q 
GlyR in more detail. Examples of currents recorded in the presence of increasing glycine 
concentrations in one cell are shown in Fig. 1A, with the dose-response curve averaged from 7 cells 
presented in Fig. 1B.  The mean glycine EC50 and nH values are summarised in Table 1.  The glycine 
EC50 was increased by about an order of magnitude relative to the wild type α1 GlyR, consistent with 
the role of N102 as a glycine binding site (Vafa et al. 1999).   The N102Q mutation had little effect on 
the picrotoxin sensitivity of α1 GlyRs (Fig. 1C, D).  As the tropisetron potentiation dose-responses 
were measured as described above for the α1 GlyR, the results are directly comparable.  Examples of 
the effects of increasing tropisetron concentrations on currents activated by 220 µM (EC30) glycine are 
shown in Fig. 5A with the averaged dose-response curves shown in Fig. 5B.  Tropisetron potentiated 
the α1N102Q GlyR with mean EC50 and nH values of 5.3 ± 2.0 fM and 1.0 ± 0.3, respectively (both n = 
5), with a maximum potentiation of 65 ± 5 % (n = 5) of the EC30 glycine current.  As none of these 
values differed significantly from the respective α1 GlyR values, we conclude that N102Q has no 
effect on the tropisetron potentiation binding site. 
 
The role of the β subunit in tropisetron inhibition 
The β subunit residue, N125, is homologous with the α1 subunit N102 residue.  To investigate 
whether Ν125 is also a determinant of tropisetron inhibition, we compared the inhibitory potencies of 
tropisetron at recombinantly expressed α1β, α1N102Qβ and α1N102QβN125D GlyRs.    Because αβ GlyR 
heteromers exhibit a drastically reduced picrotoxin sensitivity relative to α homomers (Pribilla et al. TM
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1992), we first confirmed the presence of β subunits by measuring the picrotoxin sensitivity of all 
heteromeric GlyRs.  Sample current responses to increasing concentrations of glycine for all 3 
heteromeric GlyRs are shown in Fig. 1A.  The averaged glycine dose-response curves shown in Fig. 
1B, with the mean parameters of best fit summarised in Table 1.  Examples of the response of the 
same GlyRs to 10 µM picrotoxin are shown in Fig. 1C.  Because the averaged picrotoxin inhibitory 
responses were significantly reduced compared to those of the respective homomers (Fig. 1D), we 
concluded that β subunits were successfully incorporated into at least the majority of functionally 
expressed GlyRs. 
Examples of the effects of increasing concentrations of tropisetron on currents activated by EC30 
glycine in cells expressing recombinant α1β, α1N102Q, α1N102Qβ and α1N102QβN125D GlyRs are shown in 
Fig. 6A.  Averaged dose-response curves are presented in Fig. 6B, with the corresponding curve for 
the α1 GlyR included as a dashed line for comparison.  All averaged curve fit parameters are 
summarised in Table 1.  The α1N102Qβ and α1β GlyRs exhibited comparable tropisetron IC50 values 
(Fig. 6B, Table 1), implying the presence of tropisetron inhibitory sites on the β subunit.  The 
α1N102QβN125D GlyR exhibited only a minor reduction in tropisetron inhibitory potency relative to that 
of the α1 N102Q β GlyR (Fig. 6B, Table 1).   This implies that the location of the β subunit inhibitory 
tropisetron site is not identical to its location on the α1 subunit. Finally, it is apparent that co-
expression of the β subunit significantly increased the mean IC50 and nH values for tropisetron 
inhibition (Fig. 6A, Table 1), indicating positive cooperativity among β subunit tropisetron inhibitory 
sites.   
 
Structure-activity relationships of tropisetron analogues 
To identify the tropisetron moiety likely to interact with N102, we compared the inhibitory 
potencies of tropisetron, atropine and SB 203186 at the α1 and α1N102Q GlyRs.  As shown in Fig. 7A, 
SB 203186 replaces the tropisetron tropane group but retains the indole rings intact.  In contrast, 
atropine retains the tropane group but disrupts the indole structure.  Examples of the effects of 
increasing concentrations of atropine and SB 203186 on the α1 GlyR are shown in Fig. 7B.  The α1 TM
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GlyR atropine dose-response, averaged from 3 cells, is shown in Fig. 7C (filled circles) and reveals 
mean IC50 and nH values of 234 ± 24 µM and 2.0 ± 0.1 (both n = 3), respectively.  These are 
comparable with the values reported previously for atropine at these receptors (Maksay et al. 1999).  
Like tropisetron, atropine did not significantly inhibit the α1N102Q GlyR at concentrations up to 500 
µM (Fig. 7C).  SB 203186 elicited a strong potentiation (Fig. 7B) but had no significant inhibitory 
effect on the α1 GlyR at concentrations up to 150 µM (n = 10).  These results indicate the tropisetron 
tropane group is essential for inhibition. 
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Discussion 
Comparison with previous results 
We were surprised to find that tropisetron potentiated the α1 GlyR at femtomolar 
concentrations. We observed significant tropisetron potentiation at EC30 and EC70 glycine 
concentrations but none at a near saturating glycine concentration (Fig. 3A).   We also found that 
tropisetron inhibited currents activated by EC30 glycine with an IC50 near 90 µM, and that this 
inhibition could be overcome by increasing the glycine concentration (Fig. 3B).  These results contrast 
in 3 respects with those of a previous electrophysiological study conducted on α1 GlyRs 
recombinantly expressed in Xenopus oocytes (Supplisson and Chesnoy-Marchais 2000).   First, 
Supplisson and Chesnoy-Marchais reported a tropisetron EC50 of around 5 µM for α1 GlyR 
homomers, although incorporation of the β subunit reduced the EC50 to the low nanomolar range.  
Second, they reported that tropisetron potentiation was apparent only at glycine concentrations of less 
than EC30.  Third, contrary to the present study they found that the tropisetron inhibitory potency was 
enhanced with increased glycine concentration.  As both studies examined the same recombinantly 
expressed GlyR subunits, these differences most likely arise as a consequence of the different 
expression systems used (Xenopus oocytes versus HEK293 cells). 
The effects of tropisetron have also been investigated on native GlyRs in embryonic spinal 
neurons (Chesnoy, 1996).  Although the tropisetron EC50 was not quantitated, a robust potentiation 
was seen at 20 nM.  Another study showed that tropisetron displaced [3H]strychnine from spinal 
neuron GlyRs at micromolar concentrations, although an additional nanomolar affinity displacement 
component was observed in the presence of glycine (Maksay, 1998).  This nanomolar component was 
associated only with those tropeine derivatives that elicited a potentiating effect.   However, it is 
difficult to relate these findings to the present study, as the potency with which tropisetron displaces 
strychnine in the presence of glycine may be different to the potency with which it potentiates glycine-
activated currents.  However, the binding data do support the present conclusion that tropisetron 
behaves as a competitive antagonist at micromolar concentrations.  The structurally-related compound, 
atropine, was also found to act as a competitive antagonist of the α1 GlyR (Maksay et al. 1999). 
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Biophysical implications of femtomolar potency 
 Femtomolar affinity implies a very fast association rate, a very slow dissociation rate and 
multiple close contact points between the bound molecule and its site (Radic et al. 2005).  Substances 
that bind with such affinity are comparatively rare in biology, although well documented examples 
exist in the case of biotin with streptavidin (Howarth et al. 2006), trifluoroacetophenones with 
acetylcholinesterase (Senapati et al. 2005; Radic et al. 2005) and zinc with metalloregulatory proteins 
(Outten and O’Halloran 2001).  The tropisetron binding or associaiton rate, kon, is unlikely to exceed 
the rate of diffusion.  In free solution, the relationship between the kon and the rate of diffusion is given 
by the Smoluchowski equation,  kon = (4 x π x N x D x r)/1000 where N is Avogadro’s number, D is 
the diffusion coefficient and r is the radius of the target on the receptor.  Using this equation, Burgen 
estimated an upper kon limit of 2.5 x 109 M-1 s-1 for drug-receptor interactions (Burgen, 1966).  This is 
comparable to the diffusion limited rate (3.6 – 8.0 x 109 M-1 s-1) with which trimethylammonio 
triacetophenone associates with acetylcholinesterase (Radic et al. 2005).  
 However, association rates for even the most energetically favourable binding interactions 
seldom approach the diffusion limited rate.  Most femtomolar binding sites lie in deep pockets, which 
means that steric hindrance by protruding structures is likely to retard binding rates.  Furthermore, 
once a drug closely approaches its receptor, intermolecular forces may either repel the molecule or 
attract it to lower affinity binding conformations.  Together, these mechanisms can strongly reduce kon.   
 The relationship between EC50 and binding affinity (KA) is given by EC50 = KA/(1+E) where E 
is efficacy (Colquhoun, 1998).  If we assume that tropisetron – GlyR interaction has low value of E (so 
that EC50 = KA) and a fast kon of 109 M-1 s-1, then its dissociation rate will be 10-5 s-1 at an EC50 of 10 
fM.  This implies that tropisetron potentiation is essentially irreversible.  It also implies that the 
equilibrium association time constant in the presence of 1 pM tropisetron is 1000 s.  This does not 
agree  well with the value of 107 ± 25 s observed in this study.  Alternately, the E value of the system 
may be high, so that the tropisetron KA is much larger than its EC50.  This would imply an extremely 
fast tropisetron-mediated receptor conformational change, but would yield a lower kon.  A slow 
dissociation rate is expected in this case as well. 
TM
PDF Editor
 
 
 15 
 A high ‘apparent affinity’ can result from a lipophilic ligand accumulating in the plasma 
membrane, thereby creating a high local concentration near a transmembrane binding site (Lee, 2004).  
It is unlikely that such a mechanism applies in the present case as tropisetron must be co-applied with 
glycine in order to effect potentiation (Fig. 2A).      
 At least two sources of error are likely to become significant when applying femtomolar 
ligand concentrations to receptors.  The first stems from the fact that the ligand concentration may be 
close to or lower than the receptor concentration, which could result in the depletion of the local ligand 
concentration but this effect is likely to be minimal as ligand is applied under continuous flow, thereby 
maintaining constant ligand concentration.  The second relates to the fact that low ligand 
concentrations equilibrate very slowly with the receptor, which makes it difficult to accurately 
measure concentration-response relationships. For these reasons, the tropisetron EC50 values measured 
in this study must be considered as order-of-magnitude approximations. 
What can explain the drastic difference in tropisetron sensitivity between HEK293 cell and 
Xenopus oocyte expression systems?  The glycinergic agonists, glycine, β-alanine and taurine all 
exhibit approximately 10-fold differences in their EC50 values depending on whether GlyRs are 
expressed HEK293 cells or Xenopus oocytes (Lynch 2004).  The minor structural changes that 
mediate these differences could have a drastic effect on the affinity of a compound that binds with 
femtomolar affinity. 
 
 
N102 as a molecular determinant of tropisetron inhibition 
The conservative α1 subunit mutation, N102Q, completely abolished tropisetron inhibition of 
α1 homomeric GlyRs although it had no effect on the magnitude or sensitivity of tropisetron 
potentiation.  We therefore conclude that N102 is a specific determinant of tropisetron inhibition.  
Several arguments suggest this residue may be an inhibitory tropisetron contact site.  First, N102 has 
previously been identified as a glycine contact site (Vafa et al. 1999; Han et al. 2001), implying its 
availability to coordinate other ligands in the binding pocket.  Furthermore, because N102 mutations 
do not affect strychnine affinity (Vafa et al. 1999) or tropisetron potentiation (this study), they are 
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unlikely to act by non-specifically disrupting the structure of the ligand-binding pocket.  Finally, an 
interaction between N102 and tropisetron is chemically plausible.  Because asparagine amine groups 
serve as H bond donors, N102 could conceivably form an H bond with the tropisetron tropane 
nitrogen.  A number of observations suggest that such an interaction may be realistic.  Selective 
substitution of the asparagine amine group with an oxygen, via the N102D mutation, abolishes 
tropisetron inhibitory potency.  A comparison of the structure-activity relationships of tropisetron, SB 
203186 and atropine indicates that the tropane group is essential for inhibition.  Docking models of 
granisetron at the 5-HT3R, which place the granisetron tropane nitrogen and the near-homologous 5-
HT3R asparagine (N128) into close physical proximity, support the steric feasibility of this proposed 
interaction (Maksay et al. 2003; Thompson et al. 2005).  Finally, a common binding site for 
tropisetron and glycine fits well with functional data showing tropisetron and its analogues acting as 
competitive antagonists (this study; Maksay 1998; Maksay et al. 1999).  
Although the tropisetron tropane nitrogen is also essential for potentiation, (Maksay 1998; 
Chesnoy-Marchais et al. 2000), the results of the present study indicate that N102 does not coordinate 
tropisetron when it binds in the potentiating mode. 
 
The role of the β subunit 
   Since heteromeric GlyRs have a 2α:3β subunit stoichiometry (Grudzinska et al. 2005), they 
contain α−β, β−β and β−α interfaces but probably not α−α interfaces.   The present study 
demonstrates that the α1 subunit N102Q mutation ablates tropisetron inhibitory binding at the α−α 
interface.   However, since the β subunit N125D mutation does not affect tropisetron inhibitory 
potency in heteromeric α1N102Qβ receptors, we conclude that tropisetron binds in a different orientation 
at the β−β, α−β and/or β-α interfaces than it does at the α−α interface.  Since the tropisetron 
inhibitory nH is significantly increased in β subunit-containing GlyRs (Table 1), positive cooperativity 
may exist between the β subunit sites. 
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Conclusion 
   This study demonstrates that tropisetron potentiates the α1 GlyR at femtomolar 
concentrations. As potentiation is observed only when tropisetron is co-applied with glycine, it is 
unlikely to be mediated by tropisetron accumulation in the cell membrane.  Our results are consistent 
with a model where tropisetron binds to its potentiating site at a rate that approaches the rate of 
diffusion and becomes coordinated so tightly that it cannot dissociate. 
 We have also shown that conservative mutations to N102 in the α1 subunit specifically ablate 
tropisetron inhibition without affecting the magnitude or sensitivity of tropisetron potentiation.  We 
tentatively suggest that N102 may directly coordinate inhibitory tropisetron via an H bond with its 
tropane nitrogen.  As N102 is in close proximity to the glycine-binding site, this would provide a 
ready explanation for the competitive nature of tropisetron inhibition.  Because mutation of the 
homologous β subunit residue, N125, does not affect tropisetron inhibitory potency in α1N102Qβ 
GlyRs, we propose that the tropisetron inhibitory binding site may vary from one subunit interface 
type to another in heteromeric GlyRs.  Finally, the results presented here provide a first step in 
defining the GlyR binding sites for a compound that is probably the most promising therapeutic lead 
yet identified for the GlyR. 
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Table 1.  Functional properties of GlyRs employed in this study. 
 
 
GlyR 
 Glycine  Tropisetron 
EC50 (µM) nH n IC50 (µM) nH n 
α1 35 ± 2 2.5 ± 0.2 10 89±13 -0.9±0.3 7 
α1β 51 ± 9 1.6 ± 0.2 6 255± 40** -2.8± 0.4*** 4 
α1N102Q 362±36*** 2.2 ± 0.1 7 no inhibition at 500 µM 8 
α1N102Qβ 133 ± 6*** 2.0 ± 0.2 6 275±54** -2.2±0.5** 6 
α1N102QβN125D  295 ± 36*** 2.2 ± 0.6 4 384±34*** -2.9±0.4*** 5 
 
*P < 0.05, ** P < 0.01, *** P < 0.001 relative to the α1 GlyR using Student’s unpaired t-test. 
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Table 2.  Sensitivity of mutant α1 GlyRs to tropisetron inhibition.  Mutations that completely 
abolished inhibition, while leaving potentiation intact, are shown in bold.  All results were averaged 
from at least 4 cells. 
α1 GlyR 
mutation 
[glycine] 
(µM)* 
% inhibition at 500 µM 
tropisetron 
wild type 20   -76 ± 12 
N46Q 25              -28 ± 4 
F63Y 60    -30 ±13 
R65K 5000 -70 ± 17 
I93A 600  -58 ± 5 
A101C 10  -49 ± 7 
N102A  800 +32  ± 10 
N102D 30 + 87 ±  9 
N102Q 220 +43  ±  8 
H107N 25    -55 ± 11 
H109N 25    -60 ± 5 
S129V 12,000    -79 ± 8 
A137S 30    -54 ± 6 
I153T 20    -42 ± 12 
F159Y 2,000 -52 ± 5 
Y161A 200  -47 ± 2 
D180E 25    -41± 6 
K200A 700 -68±10 
H201A 30    -84 ± 10 
Y202F 8,000 -64 ± 3 
N203A 30 -64 ± 10 
T204A 10,000 -48 ± 12 
S267C 25 -48 ± 8 
* This indicates the EC30 glycine concentration used to assay the tropisetron inhibitory potency. 
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Figure Legends 
Figure 1.  Glycine and picrotoxin sensitivities of GlyRs employed in this study.  A.  Examples 
of currents activated by the indicated glycine concentrations in cells expressing the indicated GlyR 
subunits.  In this and all subsequent figures, inward currents are represented as downward deflections 
and glycine was applied for the period represented by the unfilled bar.  The horizontal 5 s scale bar 
applies to all traces displayed in this figure.  B.  Averaged dose-responses for all GlyRs examined in 
this study.  Mean parameters of best fit are given in Table 1.  Symbols presented in the legend apply to 
panels B and D.  C.  Examples of the inhibitory effects of 10 µM picrotoxin on currents activated by 
EC30 glycine in cells expressing the indicated GlyRs.  Picrotoxin was applied for the period indicated 
by the filled bar.  D.  Averaged inhibition produced by 10 µM picrotoxin at each of the 5 tested GlyRs.  
A Student’s unpaired t-test was used to assess statistical significance, with *P < 0.05, ** P < 0.01, *** P 
< 0.001 representing significance relative to the α1 GlyR. 
Figure 2.  Tropisetron effects on the α1 GlyR.  In this and all subsequent figures, tropisetron 
application is indicated by the filled bars. A.  (Upper panel) A continuous recording showing the effect 
on glycine current magnitude of repeated 10 s applications of 1 pM tropisetron.  Periodic applications 
of saturating (2 mM) glycine reveal that the saturating current magnitude remains constant.  The lower 
panel shows a similar experiment except that cells were exposed to a single 90 s application of 1 pM 
tropisetron in the closed state.   B.  Plot of current magnitude versus cumulative exposure time to 1 pM 
tropisetron for the data shown in A (upper panel).  The curve is an exponential fit with a time constant 
of 39 s.  C.  A sample potentiating dose-response (upper panel) and averaged potentiating dose-
responses from 5 cells expressing α1 GlyRs (lower panel).  The vertical axis is plotted as (I – 
IEC30)/Imax, where IEC30 is the control current in absence of tropisetron, I is the current in the presence of 
a given concentration of tropisetron and Imax is the maximum amplitude of the tropisetron-potentiated 
current.  Curve fit parameters of best fit are displayed in the text.  D.  A sample inhibiting dose-
response (upper panel) and averaged inhibitory dose-responses from 5 cells expressing α1 GlyRs 
(lower panel).  Imax is the maximum amplitude of the tropisetron-potentiated current.  Curve fit 
parameters of best fit are displayed in Table 1. TM
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Figure 3. Glycine dose-dependence of tropisetron potentiation and inhibition.  A.  (Left panel)  
Examples of currents activated by EC30, EC70 and EC90 glycine concentrations in different cells 
expressing α1 GlyRs, together with the effect of a co-application of 10 nM tropisetron.  The right 
panel shows the mean percentage tropisetron potentiation averaged from 5 cells at each glycine 
concentration.  A Student’s unpaired t-test was used to assess statistical significance, with ** P < 0.01 
representing significance relative to the α1 GlyR.  B.  (Left panel)  Examples of currents activated by 
EC30, EC70 and EC100 glycine concentrations in a cell expressing α1 GlyRs, together with the effect of 
a co-application of 200 µM tropisetron.  The right panel shows the percentage of current remaining 
averaged from 5 cells at each glycine concentration.  A Student’s paired t-test was used to assess 
statistical significance, with *** P < 0.001 representing significance relative to the α1 GlyR.   
Figure 4.  Model of the extracellular domain of the homomeric α1 GlyR built by homology with 
the AChBP structure previously as described (Nevin et al. 2003).  Two of the five subunits are 
displayed as ribbons coloured by subunit. The model is viewed parallel to the membrane showing the 
outer surface of the pentameric ring, with the membrane at the bottom of the figure. The putative 
agonist-binding site is situated behind the orange overlapping loop at the centre of the figure. A 
selection of residues that have been mutated in this study are shown as bonds, coloured by atom.  
Figure 5.  Tropisetron potentiation and inhibition of the α1N102Q GlyR.  A.  Examples of currents 
activated by the indicated glycine concentrations in a cell expressing α1N102Q GlyRs.  B.  Averaged 
potentiating dose-responses from 5 cells.  The vertical axis is plotted as (I – IEC30)/Imax, where IEC30 is 
the control current in absence of tropisetron, I is the current in the presence of a given concentration of 
tropisetron and Imax is the maximum amplitude of the tropisetron-potentiated current.  Parameters of 
best fit are given in the text.  The corresponding curve for the α1 GlyR (dashed line) is included for 
comparison. 
Figure 6.  Determinants of tropisetron inhibitory sensitivity.  A.  Examples of the effect of 
indicated tropisetron concentrations on currents activated by EC30 glycine in cells expressing the 
indicated GlyRs.  B.  Averaged tropisetron inhibitory dose-response curves for the indicated GlyRs.  
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Imax is the maximum amplitude of the tropisetron-potentiated current.  Parameters of best fit are given 
in Table 1.  The corresponding curve for the α1 GlyR (dashed line) is included for comparison. 
Figure 7.  Structure-activity relationships of tropisetron analogues.  A.  Structures of tropisetron 
and related compounds investigated in this study.  The granisetron structure is included as its binding 
site at the 5-HT3R has been thoroughly investigated.  B.  Examples of the effect of indicated 
concentrations of atropine and SB203186 on currents activated by EC30 glycine in cells expressing α1 
GlyRs.  Note the complete absence of inhibition induced by SB203186.  B.  Averaged inhibitory dose-
response curves for atropine at the α1 and α1N102Q GlyRs.  Parameters of best fit for the α1 GlyR 
curve are given in the text. 
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